Galcetin - 3 and Cardiorenal Disease

Authors

  • Luca Di Lullo U.O.C. Nefrologia e Dialisi, Ospedale Parodi-Delfino, Colleferro (RM)
  • Rodolfo Rivera Divisione di Nefrologia, Ospedale S. Gerardo, Monza
  • Fulvio Floccari U.O.C. Nefrologia e Dialisi, Ospedale S. Paolo, Civitavecchia (RM)
  • Vincenzo Barbera U.O.C. Nefrologia e Dialisi, Ospedale Parodi-Delfino, Colleferro (RM)
  • Antonio Bellasi U.O.C. Nefrologia e Dialisi, ASST Lariana, Como
  • Antonio De Pascalis U.O.C. Nefrologia e Dialisi, Ospedale V. Fazzi, Lecce
  • Domenico Russo Cattedra di Nefrologia, Università degli Studi Federico II, Napoli
  • Luigi Russo Cattedra di Nefrologia, Università degli Studi Federico II, Napoli
  • Francesca Santoboni U.O.C. Nefrologia e Dialisi, Ospedale Parodi-Delfino, Colleferro (RM)
  • Giovanni Otranto U.O.C. Nefrologia e Dialisi, Ospedale Parodi-Delfino, Colleferro (RM)
  • Claudio Ronco International Renal Research Institute, Ospedale S. Bortolo, Vicenza

DOI:

https://doi.org/10.33393/gcnd.2017.621

Keywords:

Acute kidney injury, Chronic kidney disease, Galectin-3, Heart failure, Nephrogenesis, Ventricular remodelling

Abstract

Galectin-3 is a 32- to 35-kDa member of the galectin family of b-galactoside-binding lectins, which is characterized by a carbohydrate recognition domain. Through its carbohydrate-binding function, it regulates cell growth, differentiation, and inflammation. It also plays a complex, context-dependent role in the kidneys. During the development, it promotes nephrogenesis and is strongly expressed in the ureteric bud and its derivatives. An increase in the concentration of galectin-3 has been reported to be associated with fibrosis of the kidneys. Elevated levels of plasma galectin-3 are also associated with increased risks of rapid renal function decline, incident chronic kidney disease, and progressive renal impairment, and also with cardiovascular endpoints, infection, and all-cause mortality in patients with renal function impairment. This review discusses a general survey on galectin-3 expressions in nephrogenesis, kidney injury in animal models, clinical renal diseases, and renal transplantation and the potential role of galectin-3 for treatment in kidney disease. (Cardionephrology)

Downloads

Download data is not yet available.

Downloads

Published

2017-01-17

How to Cite

Di Lullo, L., Rivera, R., Floccari, F., Barbera, V., Bellasi, A., De Pascalis, A., Russo, D., Russo, L., Santoboni, F., Otranto, G., & Ronco, C. (2017). Galcetin - 3 and Cardiorenal Disease. Giornale Di Clinica Nefrologica E Dialisi, 29(1), 50–58. https://doi.org/10.33393/gcnd.2017.621

Issue

Vol. 29 No. 1 (2017): January-March 2017

Section

Cardionephrology

License

Authors contributing to Giornale di Clinica Nefrologica e Dialisi (GCND) agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.

Metrics

Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)

1 2 3 4 > >>